ADMA Biologics, Inc. (ADMA) Financials
Key financial figures for ADMA Biologics, Inc. (Q2 2026).
ADMA Biologics, Inc. reported revenue of $124.4 million for Q2 FY2026, up 2.0% from the same period a year earlier. Net income was $37.8 million, or $0.16 per share. Operating margin came to 42.16%, against 35.08% a year earlier. Free cash flow for the period was $27.3 million. Across the last 5 reported quarters, quarterly revenue has risen from $122.0 million in Q2 FY2025 to $124.4 million in Q2 FY2026. The figures above are as filed, and the full income statement, balance sheet and cash flow history for ADMA Biologics, Inc. are on the SentiSense financials page.
- Revenue
- $124M
- Net Income
- $38M
- EPS
- $0.17
- Total Assets
- $684M
- Operating Cash Flow
- $30M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q2 FY2026 | $124M | $38M | $0.16 | 42.16% | $27M |
| Q1 FY2026 | $114M | $45M | $0.19 | 50.9% | $56M |
| Q4 FY2025 | $139M | $49M | $0.20 | 45.09% | $35M |
| Q3 FY2025 | $134M | $36M | $0.15 | 38.01% | -$1M |
| Q2 FY2025 | $122M | $34M | $0.14 | 35.08% | $19M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $510M | $147M | $0.60 | 37.53% | $28M |
| FY2024 | $426M | $198M | $0.81 | 32.59% | $110M |
| FY2023 | $258M | -$28M | -$0.13 | 8.38% | $4M |
Frequently asked questions
What was ADMA Biologics, Inc.'s revenue last quarter?
ADMA Biologics, Inc. reported revenue of $124.4 million for Q2 FY2026, up 2.0% from the same period a year earlier.
Is ADMA Biologics, Inc. profitable?
Yes. ADMA Biologics, Inc. reported net income of $37.8 million for Q2 FY2026, a net margin of 30.4% on revenue.
How has ADMA Biologics, Inc.'s margin trended?
Operating margin was 42.16% in Q2 FY2026, compared with 35.08% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did ADMA Biologics, Inc. generate?
ADMA Biologics, Inc. generated free cash flow of $27.3 million in Q2 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for ADMA Biologics, Inc. on SentiSense, with up to forty quarters and twenty fiscal years of history.